Liise-anne Pirofski
#86,236
Most Influential Person Now
American immunologist
Liise-anne Pirofski's AcademicInfluence.com Rankings
Liise-anne Pirofskibiology Degrees
Biology
#4754
World Rank
#7052
Historical Rank
#1731
USA Rank
Immunology
#394
World Rank
#409
Historical Rank
#81
USA Rank
Download Badge
Biology
Liise-anne Pirofski's Degrees
- Doctorate Medicine Albert Einstein College of Medicine
- PhD Microbiology and Immunology Albert Einstein College of Medicine
Why Is Liise-anne Pirofski Influential?
(Suggest an Edit or Addition)According to Wikipedia, Liise-anne Pirofski is a Professor of Medicine, Microbiology and Immunology at Albert Einstein College of Medicine and Montefiore Medical Center. She is a Member of the Association of American Physicians, and a Fellow of the American Association for the Advancement of Science, American Academy of Microbiology, American College of Physicians and the Infectious Diseases Society of America.
Liise-anne Pirofski's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The convalescent sera option for containing COVID-19. (2020) (826)
- Deployment of convalescent plasma for the prevention and treatment of COVID-19. (2020) (684)
- Host-Pathogen Interactions: Redefining the Basic Concepts of Virulence and Pathogenicity (1999) (664)
- The damage-response framework of microbial pathogenesis (2003) (519)
- Host-Pathogen Interactions: Basic Concepts of Microbial Commensalism, Colonization, Infection, and Disease (2000) (491)
- Passive antibody therapy for infectious diseases (2004) (475)
- Host-pathogen interactions: the attributes of virulence. (2001) (400)
- Characterization of a Murine Monoclonal Antibody toCryptococcus neoformans Polysaccharide That Is a Candidate for Human Therapeutic Studies (1998) (294)
- Antibody-mediated regulation of cellular immunity and the inflammatory response. (2003) (167)
- Characterization of protective extracellular membrane-derived vesicles produced by Streptococcus pneumoniae. (2014) (166)
- A reappraisal of humoral immunity based on mechanisms of antibody-mediated protection against intracellular pathogens. (2006) (154)
- Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host (1998) (151)
- Accidental Virulence, Cryptic Pathogenesis, Martians, Lost Hosts, and the Pathogenicity of Environmental Microbes (2007) (142)
- On Virulence (2010) (138)
- Immunoglobulins in defense, pathogenesis, and therapy of fungal diseases. (2012) (134)
- A new synthesis for antibody-mediated immunity (2011) (133)
- Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity (2009) (124)
- A Cryptococcal Capsular Polysaccharide Mimotope Prolongs the Survival of Mice with Cryptococcus neoformans Infection1 (2001) (122)
- Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection. (1993) (117)
- The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis (2021) (109)
- Virulence factors and their mechanisms of action: the view from a damage-response framework. (2009) (109)
- Mouse adenovirus type 1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice (1995) (106)
- Microbiology: Ditch the term pathogen (2014) (105)
- A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition (2020) (101)
- Host immunity to Cryptococcus neoformans. (2015) (101)
- The Absence of Serum IgM Enhances the Susceptibility of Mice to Pulmonary Challenge with Cryptococcus neoformans (2010) (101)
- Antibodies to the Cryptococcus neoformans capsular glucuronoxylomannan are ubiquitous in serum from HIV+ and HIV− individuals (1995) (101)
- Cryptococcosis in children with AIDS. (1999) (99)
- Q and A What is a pathogen? A question that begs the point (2012) (95)
- A replication-competent vesicular stomatitis virus for studies of SARS-CoV-2 spike-mediated cell entry and its inhibition (2020) (93)
- A Randomized Trial of Convalescent Plasma for COVID-19-Potentially Hopeful Signals. (2020) (89)
- Polysaccharides, mimotopes and vaccines for fungal and encapsulated pathogens. (2001) (88)
- What Is a Host? Incorporating the Microbiota into the Damage-Response Framework (2014) (87)
- X-Linked Immunodeficient Mice Exhibit Enhanced Susceptibility to Cryptococcus neoformans Infection (2013) (87)
- Induced humoral immunity and vaccination against major human fungal pathogens. (2002) (85)
- A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. (1998) (84)
- Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy (2020) (82)
- The Damage-Response Framework of Microbial Pathogenesis and Infectious Diseases (2008) (81)
- Microbial Virulence as an Emergent Property: Consequences and Opportunities (2011) (79)
- Antibodies reactive with the cryptococcal capsular polysaccharide glucuronoxylomannan are present in sera from children with and without human immunodeficiency virus infection. (1999) (78)
- CD8+ Cells Enhance Resistance to Pulmonary Serotype 3 Streptococcus pneumoniae Infection in Mice (2011) (78)
- New Concepts in Antibody-Mediated Immunity (2004) (77)
- Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine (1995) (77)
- Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan (1994) (75)
- Adjunctive immune therapy for fungal infections. (2001) (74)
- Antibody Response to Cryptococcus neoformans Proteins in Rodents and Humans (1999) (74)
- Immune therapy for infectious diseases at the dawn of the 21st century: the past, present and future role of antibody therapy, therapeutic vaccination and biological response modifiers. (2003) (71)
- Influence of Neutropenia on the Course of Serotype 8 Pneumococcal Pneumonia in Mice (2007) (71)
- Insights into mechanisms of antibody-mediated immunity from studies with Cryptococcus neoformans. (2005) (69)
- Immunogenicity and Efficacy of Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan Peptide Mimotope-Protein Conjugates in Human Immunoglobulin Transgenic Mice (2004) (67)
- The role of pneumolysin in mediating lung damage in a lethal pneumococcal pneumonia murine model (2007) (64)
- A semisynthetic Streptococcus pneumoniae serotype 8 glycoconjugate vaccine (2017) (64)
- Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody (1997) (62)
- Use of convalescent plasma in COVID‐19 patients with immunosuppression (2021) (61)
- IgM(+) memory B cell expression predicts HIV-associated cryptococcosis status. (2009) (61)
- Quantitative and qualitative differences in the serum antibody profiles of human immunodeficiency virus-infected persons with and without Cryptococcus neoformans meningitis. (1999) (61)
- Immune-Mediated Damage Completes the Parabola: Cryptococcus neoformans Pathogenesis Can Reflect the Outcome of a Weak or Strong Immune Response (2017) (60)
- A Peptide Mimotope of Type 8 Pneumococcal Capsular Polysaccharide Induces a Protective Immune Response in Mice (2005) (59)
- The meaning of microbial exposure, infection, colonisation, and disease in clinical practice. (2002) (59)
- Protective and Nonprotective Human Immunoglobulin M Monoclonal Antibodies to Cryptococcus neoformans Glucuronoxylomannan Manifest Different Specificities and Gene Use Profiles (2004) (57)
- Current concepts in host–microbe interaction leading to pneumococcal pneumonia (2013) (55)
- What Is a Host? Attributes of Individual Susceptibility (2017) (54)
- Qualitative change in antibody responses of human immunodeficiency virus-infected individuals to pneumococcal capsular polysaccharide vaccination associated with highly active antiretroviral therapy. (2003) (54)
- Antibody-Mediated Protection through Cross-Reactivity Introduces a Fungal Heresy into Immunological Dogma (2007) (54)
- Human antibodies elicited by a pneumococcal vaccine express idiotypic determinants indicative of V(H)3 gene segment usage. (1998) (53)
- SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy. (2020) (53)
- Vaccination against infectious disease following hematopoietic stem cell transplantation. (2001) (53)
- Feasibility of Radioimmunotherapy of Experimental Pneumococcal Infection (2004) (52)
- Fc Gamma Receptor 3A Polymorphism and Risk for HIV-Associated Cryptococcal Disease (2013) (52)
- Efficacy of Opsonic and Nonopsonic Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal Antibodies against Intranasal Challenge with Streptococcus pneumoniae in Mice (2009) (52)
- Towards a vaccine for Cryptococcus neoformans: principles and caveats. (2006) (52)
- Extracellular proteins of Cryptococcus neoformans and host antibody response (1997) (52)
- Antifungal Activity of a Human Antiglucuronoxylomannan Antibody (1998) (51)
- Pathogenesis of COVID-19 from the Perspective of the Damage-Response Framework (2020) (51)
- The weapon potential of a microbe (2004) (51)
- Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodies (1996) (50)
- The outcome of Cryptococcus neoformans intracellular pathogenesis in human monocytes (2009) (49)
- A Semi-synthetic Oligosaccharide Conjugate Vaccine Candidate Confers Protection against Streptococcus pneumoniae Serotype 3 Infection. (2016) (49)
- Structure-Function Relationships for Human Antibodies to Pneumococcal Capsular Polysaccharide from Transgenic Mice with Human Immunoglobulin Loci (2002) (48)
- Therapeutic Efficacy of a Conjugate Vaccine Containing a Peptide Mimotope of Cryptococcal Capsular Polysaccharide Glucuronoxylomannan (2008) (46)
- Production of Protective Human Antipneumococcal Antibodies by Transgenic Mice with Human Immunoglobulin Loci (2000) (46)
- The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19 (2021) (46)
- Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence (2021) (45)
- Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC (2020) (45)
- SARS-Cov2 variants and convalescent plasma: reality, fallacies, and opportunities. (2021) (45)
- Designed reduction of Streptococcus pneumoniae pathogenicity via synthetic changes in virulence factor codon-pair bias. (2011) (43)
- A pneumococcal capsular polysaccharide vaccine induces a repertoire shift with increased VH3 expression in peripheral B cells from human immunodeficiency virus (HIV)-uninfected but not HIV-infected persons. (2000) (43)
- Haemophilus influenzae type b bacteremia in adults with AIDS and at risk for AIDS. (1992) (42)
- A Human Monoclonal Immunoglobulin M Reduces Bacteremia and Inflammation in a Mouse Model of Systemic Pneumococcal Infection (2007) (41)
- Molecular and Functional Characteristics of a Protective Human Monoclonal Antibody to Serotype 8 Streptococcus pneumoniae Capsular Polysaccharide (1999) (41)
- Microbial virulence results from the interaction between host and microorganism. (2003) (41)
- Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis (2020) (41)
- Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi? (1996) (40)
- Antibodies to Streptococcus pneumoniae Capsular Polysaccharide Enhance Pneumococcal Quorum Sensing (2011) (38)
- Rethinking T cell immunity in oropharyngeal candidiasis (2009) (37)
- Immunomodulators as an antimicrobial tool (2006) (37)
- Molecular Characterization of the Early B Cell Response to Pulmonary Cryptococcus neoformans Infection (2012) (37)
- Exploiting the Redundancy in the Immune System (2003) (36)
- IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms. (2012) (36)
- Polysaccharide-containing conjugate vaccines for fungal diseases. (2006) (35)
- Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency? (2012) (35)
- Commentary: IDSA guidelines for improving the teaching of preclinical medical microbiology and infectious diseases. (2010) (35)
- Cryptococcus neoformans-Reactive and Total Immunoglobulin Profiles of Human Immunodeficiency Virus-Infected and Uninfected Ugandans (2005) (34)
- COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes (2022) (34)
- Understanding vaccine hesitancy in COVID-19 (2021) (34)
- The Damage–Response Framework as a Tool for the Physician-Scientist to Understand the Pathogenesis of Infectious Diseases (2018) (34)
- Modulation of the Lung Inflammatory Response to Serotype 8 Pneumococcal Infection by a Human Immunoglobulin M Monoclonal Antibody to Serotype 8 Capsular Polysaccharide (2005) (34)
- The Ebola Epidemic Crystallizes the Potential of Passive Antibody Therapy for Infectious Diseases (2015) (34)
- Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients (2021) (32)
- Vaccines for the prevention of diseases caused by potential bioweapons. (2004) (31)
- Characterization of the SARS-CoV-2 S Protein: Biophysical, Biochemical, Structural, and Antigenic Analysis (2020) (30)
- Feasibility and prospects for a vaccine to prevent cryptococcosis. (2005) (29)
- Modulation of Polymorphonuclear Cell Interleukin-8 Secretion by Human Monoclonal Antibodies to Type 8 Pneumococcal Capsular Polysaccharide (2003) (29)
- Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC (2021) (28)
- A Serotype 3 Pneumococcal Capsular Polysaccharide-Specific Monoclonal Antibody Requires Fcγ Receptor III and Macrophages To Mediate Protection against Pneumococcal Pneumonia in Mice (2012) (28)
- What is a pathogen? (2002) (28)
- Bundle in the Bronx: Impact of a Transition-of-Care Outpatient Parenteral Antibiotic Therapy Bundle on All-Cause 30-Day Hospital Readmissions (2017) (28)
- Antibody Response to Cryptococcus neoformans Capsular Polysaccharide Glucuronoxylomannan in Patients after Solid-Organ Transplantation (2006) (28)
- COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors (2021) (27)
- The weapon potential of human pathogenic fungi. (2006) (27)
- Developing Interactive Antimicrobial Stewardship and Infection Prevention Curricula for Diverse Learners: A Tailored Approach (2017) (27)
- Pneumococcal Capsular Polysaccharide Vaccine-Mediated Protection against Serotype 3 Streptococcus pneumoniae in Immunodeficient Mice (2007) (26)
- Septic shock caused by Pseudomonas paucimobilis. (1992) (25)
- Specificity and Diversity of Antibodies to Mycobacterium tuberculosis Arabinomannan (2003) (25)
- Tissue-Expressed B7x Affects the Immune Response to and Outcome of Lethal Pulmonary Infection (2012) (25)
- Therapeutic use of convalescent plasma in COVID-19 patients with immunodeficiency: A systematic review (2020) (25)
- The innate immune response to Streptococcus pneumoniae in the lung depends on serotype and host response. (2011) (24)
- Association of Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With COVID-19 (2022) (24)
- Murine adenovirus infection of SCID mice induces hepatic lesions that resemble human Reye syndrome. (1991) (24)
- Naïve B cells reduce fungal dissemination in Cryptococcus neoformans infected Rag1−/− mice (2017) (24)
- Association Between Plasma Antibody Responses and Risk for Cryptococcus-Associated Immune Reconstitution Inflammatory Syndrome (2018) (23)
- Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma (2022) (22)
- Exserohilum rostratum fungal meningitis associated with methylprednisolone injections. (2013) (22)
- Functional convalescent plasma antibodies and pre-infusion titers shape the early severe COVID-19 immune response (2021) (22)
- Quantitative and Qualitative Antibody Responses to Immunization With the Pneumococcal Polysaccharide Vaccine in HIV-Infected Patients After Initiation of Antiretroviral Treatment: Results From a Randomized Clinical Trial. (2015) (22)
- Improved Survival of Mice Deficient in Secretory Immunoglobulin M following Systemic Infection with Cryptococcus neoformans (2009) (21)
- What is infectiveness and how is it involved in infection and immunity? (2015) (20)
- Early Infectious Disease Consultation Is Associated With Lower Mortality in Patients With Severe Sepsis or Septic Shock Who Complete the 3-Hour Sepsis Treatment Bundle (2019) (20)
- Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody (2016) (20)
- The Assessment of Convalescent Plasma Efficacy against COVID-19 (2020) (19)
- In fatal COVID-19, the immune response can control the virus but kill the patient (2020) (19)
- The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis (2021) (19)
- The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages. (2010) (18)
- Antibody and B Cell Subset Perturbations in Human Immunodeficiency Virus-Uninfected Patients With Cryptococcosis (2017) (18)
- Aggregation of Streptococcus pneumoniae by a Pneumococcal Capsular Polysaccharide-Specific Human Monoclonal IgM Correlates with Antibody Efficacy In Vivo (2010) (18)
- Risk factors associated with poor response to COVID-19 vaccination in kidney transplant recipients (2021) (16)
- Primary group A streptococcal peritonitis in adults. (1990) (16)
- An ahemolytic pneumolysin of Streptococcus pneumoniae manipulates human innate and CD4⁺ T-cell responses and reduces resistance to colonization in mice in a serotype-independent manner. (2014) (15)
- CD8+ T cells and Risk for Bacterial Pneumonia and All-Cause Mortality Among HIV-Infected Women (2012) (14)
- Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan. (2004) (14)
- Help is on the way: Monoclonal antibody therapy for multi-drug resistant bacteria (2017) (14)
- Human IgM Inhibits the Formation of Titan-Like Cells in Cryptococcus neoformans (2020) (14)
- Of Mice and Men, Revisited: New Insights into an Ancient Molecule from Studies of Complement Activation by Cryptococcus neoformans (2006) (14)
- Prevalence of MRSA in Respiratory cultures and Diagnostic Performance of the MRSA Nasal PCR In Patients hospitalized with COVID-19 Pneumonia. (2020) (13)
- The potential of antibody-mediated immunity in the defence against biological weapons (2005) (13)
- Cryptococcus neoformans infection in Human Immunodeficiency Virus (HIV)-infected and HIV-uninfected patients at an inner-city tertiary care hospital in the Bronx. (2019) (13)
- A Capsular Polysaccharide-Specific Antibody Alters Streptococcus pneumoniae Gene Expression during Nasopharyngeal Colonization of Mice (2018) (12)
- The state of latency in microbial pathogenesis. (2020) (12)
- Characterization of Gene Use and Efficacy of Mouse Monoclonal Antibodies to Streptococcus pneumoniae Serotype 8 (2010) (11)
- Is Burnout Infectious? Understanding Drivers of Burnout and Job Satisfaction Among Academic Infectious Diseases Physicians (2019) (11)
- Benefits and Costs of Animal Virulence for Microbes (2019) (10)
- Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in respiratory cultures and diagnostic performance of the MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia (2020) (10)
- Mixed staphylococcal and cryptococcal epidural abscess in a patient with AIDS. (1990) (10)
- Current state of the hybridoma technology (1990) (10)
- Double-Edged Role of Interleukin 17A in Streptococcus pneumoniae Pathogenesis During Influenza Virus Coinfection. (2019) (9)
- Fungemia caused by Aureobasidium pullulans in a patient with advanced AIDS: a case report and review of the medical literature (2018) (9)
- FcγRIIa Polymorphism in Human Immunodeficiency Virus-Infected Children with Invasive Pneumococcal Disease (1997) (9)
- Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. (2020) (8)
- Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts (2021) (8)
- Fungal infections in children with human immunodeficiency virus infection (2001) (8)
- Antimicrobial Therapy in the Context of the Damage-Response Framework: the Prospect of Optimizing Therapy by Reducing Host Damage (2019) (8)
- "Anti-virulence" genes--further muddling the lexicon? Response from Arturo Casadevall and Liise-anne Pirofski. (2003) (7)
- Development, clinical translation, and utility of a COVID-19 antibody test with qualitative and quantitative readouts (2020) (7)
- A Therapeutic Vaccine for Recurrent Vulvovaginal Candidiasis. (2018) (7)
- VH3 Antibody Response to Immunization with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Elderly Persons (2011) (6)
- Risk factors of laryngeal cryptococcosis: A case report (2019) (6)
- Exploiting the Redundancy in the Immune System: Vaccines Can Mediate Protection by Eliciting ‘Unnatural’ Immunity (2003) (6)
- Functional Antibodies in COVID-19 Convalescent Plasma (2021) (6)
- Isolation and Characterization of Human Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide 3 (2021) (5)
- A Structural Model for the Ligand Binding of Pneumococcal Serotype 3 Capsular Polysaccharide-Specific Protective Antibodies (2021) (5)
- Life as an Infectious Diseases Physician Scientist: Science is Humanity's Lifeline. (2017) (5)
- WHO covid-19 drugs guideline: reconsider using convalescent plasma (2022) (5)
- Antibody Responses in HIV-Infected Patients With Advanced Immunosuppression and Asymptomatic Cryptococcal Antigenemia (2018) (5)
- VH3 gene expression in children with HIV infection. (2004) (5)
- Anorectal Testing for Monkeypox Virus Infection in Men who have Sex with Men with and without Proctitis. (2022) (5)
- COVID-19 convalescent plasma and randomized clinical trials: rebuilding confidence by explaining failures and finding signals of efficacy. (2021) (5)
- Guidance on the use of convalescent plasma to treat immunocompromised patients with COVID-19. (2023) (4)
- Why antibodies disobey the Hippocratic Oath and end up doing harm: a new clue. (2010) (4)
- Post-severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Treatment Hospitalizations as a Sentinel for Emergence of Viral Variants in New York City (2021) (4)
- Acquired Antibody-Mediated Immunity to Fungi (2006) (4)
- Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy (2020) (3)
- Extracellular Vesicles from Different Pneumococcal Serotypes Are Internalized by Macrophages and Induce Host Immune Responses (2021) (3)
- The damage response framework and infection prevention: From concept to bedside (2020) (3)
- Is SARS‐CoV‐2 viral clearance in nasopharyngeal swabs an appropriate surrogate marker for clinical efficacy of neutralising antibody‐based therapeutics? (2021) (3)
- Q&A: What is a pathogen? A question that begs the point (2012) (3)
- Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma: A Systematic review and meta-analysis (2023) (2)
- Fc gammaRIIa polymorphism in human immunodeficiency virus-infected children with invasive pneumococcal disease. (1997) (2)
- Disease Severity and Durability of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Response: A View Through the Lens of the Second Year of the Pandemic (2021) (2)
- Unexpected case of cryptococcal meningoencephalitis in a patient with long-standing well-controlled HIV infection (2021) (2)
- Variable region gene utilization and mutation in a group of neutralizing murine anti-human immunodeficiency virus type 1 principal neutralizing determinant antibodies. (1993) (2)
- Traitement anti-infectieux par anticorps (2001) (2)
- A new synthesis for antibody-mediated (2012) (2)
- Vaccines and Antibody Therapies from Cryptococcus neoformans to Melanoma (2011) (2)
- Antibody Immunity and Natural Resistance to Cryptococcosis (2019) (2)
- 228Building Bridges: Improving Antibiotic Prescribing in the Emergency Department (2014) (1)
- Protease Inhibitors Do Not Affect Antibody Responses to Pneumococcal Vaccination (2016) (1)
- Elucidating the role of procalcitonin as a biomarker in hospitalized COVID-19 patients (2022) (1)
- Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy (2022) (1)
- Clinical mycology today: A synopsis of the mycoses study group education and research consortium (MSGERC) second biennial meeting, September 27-30, 2018, Big Sky, Montana, a proposed global research agenda. (2020) (1)
- Pneumococcal Vaccine With Unknown Vaccination Status (2000) (1)
- Adenovirus, Infection and Immunity (1998) (1)
- A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy (2022) (1)
- Assessment of unvaccinated and vaccinated patients with coronavirus disease 2019 (COVID-19) treated with monoclonal antibodies during the delta wave (July 1–August 20, 2021): a retrospective observational monocentric study (2022) (1)
- V H 3 Antibody Response to Immunization with Pneumococcal Polysaccharide Vaccine in Middle-Aged and Elderly Persons (cid:1) (2011) (1)
- Carbohydrate-Based Antifungal Vaccines (2008) (1)
- Efficacy and longevity of immune response to 3rd COVID-19 vaccine and effectiveness of a 4th dose in severely immunocompromised patients with cancer (2022) (1)
- Dialysis Clinic (1995) (1)
- Association of Decreased Cryptococcal Antibody Levels With Cryptococcosis-Associated Immune Reconstitution Inflammatory Syndrome (2016) (0)
- Q U E S T I O N & A N S W E R Open Access (2012) (0)
- Pulmonary Infection Response to and Outcome of Lethal Tissue-Expressed B7x Affects the Immune (2012) (0)
- Immunotherapy for Medical Mycoses (2008) (0)
- 2034. Natural Antibodies Affects the Formation of Titan Cells in Cryptococcus neoformans In Vitro (2018) (0)
- Virulence profile: Liise-anne Pirofski (2017) (0)
- GUEST Antibody-Mediated Protection through Cross-Reactivity Introduces a Fungal Heresy into Immunological Dogma (cid:1) (2007) (0)
- Cryptococcal Antigen Screening and Missed Opportunities for Earlier Diagnosis Among People With HIV and Poor Virologic Control in the Bronx, NY (2022) (0)
- Response to Fehr and Ochsenbein: ‘Good’, ‘bad’ and ‘neutral’ antibodies depend on the host–microbe interaction (2004) (0)
- Fab of 5.6 monoclonal mouse IgG1 co-crystallized with the trisaccharide form of serotype 3 pneumococcal capsular polysaccharide (2021) (0)
- Aggregation of Streptococcus pneumoniae by a Pneumococcal Capsular Polysaccharide-Specific Human Monoclonal IgM Correlates with Antibody Efficacy In Vivo (cid:1) (2010) (0)
- Rethinking Susceptibility to Cryptococcosis (2014) (0)
- Why Isnt My Patient Getting Better? Revisiting the Disease in Infectious Diseases (2014) (0)
- Current state of the hybridoma technology. Discussion (1990) (0)
- A semisynthetic serotype 8 glycoconjugate vaccine. (2017) (0)
- Oropharyngeal Bacterial Community Composition Correlates with Baseline and Post-Vaccination Pneumococcal Polysaccharide Antibody Levels in HIV-Infected Subjects (2017) (0)
- What's Hot in ID Basic Science (2015) (0)
- Evaluation of Clinical Outcomes After Introduction of a Dedicated Infectious Diseases–Critical Care Medicine Service in Critical Care Units (2021) (0)
- Clinical Features of Crytococcus neoformans Infection in Human Immunodeficiency Virus (HIV)–Infected and HIV-Uninfected Patients (2016) (0)
- mBio Welcomes Clinical Research Papers That Advance Our Understanding of Human-Microbe Interactions (2022) (0)
- ID Basic Science (2016) (0)
- Cryptococcus neoformans Challenge with Susceptibility of Mice to Pulmonary The Absence of Serum IgM Enhances the (2010) (0)
- Improved Survival of Mice Deficient in Secretory Immunoglobulin M following Systemic Infection with Cryptococcus neoformans (cid:1) † (2009) (0)
- Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial (2023) (0)
- Antimicrobial Stewardship-Driven Monoclonal Antibody Treatment Program for COVID-19 Patients in the Bronx, New York (2021) (0)
- Cryptococcus neoformans–Specific and Non–Cryptococcus neoformans–Specific Antibody Profiles in Organ Transplant Recipients With and Without Cryptococcosis (2022) (0)
- Infection Cryptococcus neoformans with Mimotope Prolongs the Survival of Mice A Cryptococcal Capsular Polysaccharide (2000) (0)
- What is infectiveness and how is it involved in infection and immunity? (2015) (0)
- 208. Early Infectious Disease Consultation is Associated with Lower Mortality in Patients with Severe Sepsis or Septic Shock who Complete the 3-hour Sepsis Bundle (2019) (0)
- Minireview Host-pathogen Interactions: Redefining the Basic Concepts of Virulence and Pathogenicity Historical Views of Microbial Pathogenicity and Virulence (0)
- Rethinking the role of COVID-19 convalescent plasma in the critically ill (2022) (0)
- Acquired Humoral Immunity to Cryptococcus neoformans (2011) (0)
- Convalescent Plasma for Covid-19. (2022) (0)
- The association of antibody immunity with cryptococcal antigenemia and mortality in a South African cohort with advanced HIV disease. (2022) (0)
- A capsular polysaccharide-specific antibody alters gene expression during nasopharyngeal colonization of mice. (2018) (0)
- Microbial Pathogenesis: The 'Damage-Response Framework' and the Lexicon of Infectious Diseases (2003) (0)
- Opening the Hood and Looking at the Mechanisms (2016) (0)
- 1316. An Integrative Approach to Teaching History of Medicine in Medical School (2018) (0)
- Molecular characterization of antigen-specific B1 and B2 B-cells populations in Cryptococcus neoformans infection in mice (43.1) (2012) (0)
- Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy. (2023) (0)
- 647. Characterization and Development of Human Monoclonal Antibodies to Pneumococcal Serotype 3 (2018) (0)
- Report from the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy and 46th Infectious Diseases Society of America Joint Conference 2008: Washington, DC, USA, October 25-28, 2008. (2009) (0)
- CRYPTOCOCCAL MENINGITIS IN AN HIV-INFECTED MAN WITH NORMAL ABSOLUTE CD4+ LYMPHOCYTE COUNT (1997) (0)
- Aharona Therapeutic Studies Polysaccharide That Is a Candidate for Human Cryptococcus neoformans Antibody to Characterization of a Murine Monoclonal (1998) (0)
- An Overview of Host Defense Against Cryptococcus (2017) (0)
- From skin cells to hepatocytes: advances in application of iPS cell technology (2010) (0)
This paper list is powered by the following services:
Other Resources About Liise-anne Pirofski
What Schools Are Affiliated With Liise-anne Pirofski?
Liise-anne Pirofski is affiliated with the following schools:
